A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma

BMC Urology

Research Article

Rodolfo B dos Reis¹  Fernando LA Fonseca²  Auro Del Giglio²  Marília D Senra²  Antônio CL Pompeo³  Ary Serpa Neto³  Marcos Tobias-Machado⁴  Marcos AP Esteves⁴  Marcelo L Wroclawski⁴ 

[1] Dept. of Urology; USP Medicine School (FMUSP-RP), Ribeirão Preto, Brazil;Research Institute; Albert Einstein Jewish Hospital (IEP-HIAE), São Paulo, Brazil;Oncology Division, Dept. of Clinical Oncology and Haematology; ABC Medical School (FMABC), Santo André, Brazil;Urologic Oncology Division; Dept. of Urology; ABC Medical School (FMABC), Santo André, Brazil;Urologic Oncology Division; Dept. of Urology; ABC Medical School (FMABC), Santo André, Brazil;Research Institute; Albert Einstein Jewish Hospital (IEP-HIAE), São Paulo, Brazil;

关键词: Prostate Cancer;    Bone Mineral Density;    Osteoporosis;    Androgen Deprivation Therapy;    Total Bone Mineral Density;   

DOI  :  10.1186/1471-2490-10-9

 received in 2009-11-25, accepted in 2010-05-19,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundOsteoporosis could be associated with the hormone therapy for metastatic prostate carcinoma (PCa) and with PCa per se. The objective of this review is to determine the incidence of bone loss and osteoporosis in patients with PCa who are or are not treated with hormone therapy (ADT).MethodsThe Medline, Embase, Cancerlit, and American Society of Clinical Oncology Abstract databases were searched for published studies on prostate cancer and bone metabolism. The outcomes assessed were: fracture, osteoporosis and osteopenia.ResultsThirty-two articles (116,911 participants) were included in the meta-analysis. PCa patients under ADT had a higher risk of osteoporosis (RR, 1.30; p < 0.00001) and a higher risk of fractures (RR, 1.17; p < 0.00001) as compared to patients not under ADT. The total bone mineral density was lower in patients under ADT when compared with patients not under ADT (p = 0.031) but it was similar to bone mineral density found in healthy controls (p = 0.895). The time of androgen deprivation therapy correlated negatively with lumbar spine and total hip bone mineral density (Spearman's rho = -0.490 and -0.773; p = 0.028 and 0.001, respectively) and with total hip t score (Spearman's rho = -0.900; p = 0.037).ConclusionWe found consistent evidence that the use of androgen deprivation therapy in patients with PCa reduces bone mineral density, increasing the risk of fractures in these patients.

【 授权许可】

Unknown   
© Serpa Neto et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.